Antimicrobial Stewardship in Cystic Fibrosis

The chronic airway infection and inflammation characteristic of cystic fibrosis (CF) ultimately leads to progressive lung disease, the primary cause of death in persons with CF (pwCF). Despite many recent advances in CF clinical care, efforts to preserve lung function in many pwCF still necessitate frequent antimicrobial use. Incorporating antimicrobial stewardship (AMS) principles into management of pulmonary exacerbations (PEx) would facilitate development of best practices for antimicrobial utilization at CF care centers. However, AMS can be challenging in CF given the unique aspects of chronic, polymicrobial infection in the CF airways, lack of evidence-based guidelines for managing PEx, limited utility for antimicrobial susceptibility testing, and increased frequency of adverse drug events in pwCF. This article describes current evidence-based antimicrobial treatment strategies for pwCF, highlights the potential for AMS to beneficially impact CF care, and provides practical strategies for integrating AMS programs into the management of PEx in pwCF. Our article aims to describe the relevant microbiology and current evidence-based antimicrobial treatment strategies for people with cystic fibrosis (CF), highlight the role of antimicrobial stewardship (AMS), and provide practical strategies to incorporate AMS programs into CF care.

Automated summary

This article provides evidence-based antimicrobial treatment strategies for people with cystic fibrosis (CF) and highlights the potential impact of antimicrobial stewardship (AMS) in CF care. It also offers practical strategies for incorporating AMS programs into the management of pulmonary exacerbations (PEx) in pwCF. The challenging aspects of chronic, polymicrobial infection unique to CF, limited guidelines for managing PEx, limited utility of antimicrobial susceptibility testing, and increased frequency of adverse drug events in pwCF pose challenges for implementing AMS in CF care.